Australia markets close in 35 minutes
  • ALL ORDS

    6,781.10
    -35.70 (-0.52%)
     
  • ASX 200

    6,558.70
    -42.40 (-0.64%)
     
  • AUD/USD

    0.7389
    -0.0001 (-0.02%)
     
  • OIL

    44.94
    -0.59 (-1.30%)
     
  • GOLD

    1,773.80
    -14.30 (-0.80%)
     
  • BTC-AUD

    25,039.00
    +240.69 (+0.97%)
     
  • CMC Crypto 200

    364.65
    +27.15 (+8.05%)
     
  • AUD/EUR

    0.6171
    -0.0002 (-0.03%)
     
  • AUD/NZD

    1.0513
    +0.0003 (+0.03%)
     
  • NZX 50

    12,768.52
    +128.69 (+1.02%)
     
  • NASDAQ

    12,258.21
    +106.01 (+0.87%)
     
  • FTSE

    6,367.58
    +4.65 (+0.07%)
     
  • Dow Jones

    29,910.37
    +37.87 (+0.13%)
     
  • DAX

    13,335.68
    +208.68 (+1.59%)
     
  • Hang Seng

    26,760.53
    -134.15 (-0.50%)
     
  • NIKKEI 225

    26,588.46
    -56.25 (-0.21%)
     

Britain partners with Oxford firm to assess coronavirus vaccine T cell responses

·1-min read

LONDON, Oct 22 (Reuters) - Britain on Thursday said it would partner with an Oxford-based firm to provide testing for the T cell response of coronavirus vaccine candidates to try to assess their immune responses.

T cell immunity is thought to be essential to protection against infection from the SARS-COV-2 coronavirus, and could provide longer term immunity than antibodies.

The UK Vaccine Taskforce has chosen Oxford Immunotec to supply T cell testing for its assessment of different vaccine candidates.

"It is important to be able to assess the different vaccines head-to-head and the T cell response is part of our portfolio of accredited assays that we are employing for cross comparisons," Kate Bingham, chair of the UK Vaccines Taskforce, said in a statement.

Britain has signed supply deals for six different coronavirus vaccine candidates, including those being made by AstraZeneca and Pfizer and BioNTech, seen as among the frontrunners in the race for a vaccine.

Oxford Immunotec said its techonology platform enabled the centralisation of fresh blood samples from different locations to measure the T cell response in a standardised way.

It said the platform, known as T-SPOT, was being used to identify the T cells made in response to the pathogen that causes tuberculosis.

(Reporting by Alistair Smout; editing by Barbara Lewis)